• Facebook
  • Twitter
  • LinkedIn
  • Google +
  • RSS

Deep vein thrombosis (DVT) - Articles and news items

edoxaban

Servier Canada to market edoxaban in Canada

Industry news / 27 June 2016 / Victoria White, Digital Content Producer

Edoxaban is an oral anticoagulant that specifically inhibits factor Xa, which is an important factor in the coagulation system that leads to blood clotting…

vte

Daiichi Sankyo helps raise awareness of VTE and AF

Industry news / 13 October 2015 / Daiichi Sankyo

Daiichi Sankyo has teamed up with World Thrombosis Day to promote awareness of thrombosis, its causes, risk factors, and signs and symptoms…

clot-edoxaban

NICE recommends edoxaban for deep vein thrombosis

Industry news / 26 August 2015 / Victoria White

NICE has recommended once-daily edoxaban for the treatment and prevention of recurrent DVT and pulmonary embolism, saying the drug is cost-effective for the NHS…

necitumumab

NICE guidance recommends anti-blood clotting drug apixaban

Industry news / 9 June 2015 / NICE

NICE has recommended the anti-blood clotting drug apixaban as an option for treating and preventing venous thromboembolism (VTE) in adults…

Lixiana

Swissmedic approves Lixiana for the prevention of stroke and systemic embolism in non-valvular atrial fibrillation

Industry news / 15 April 2015 / Daiichi Sankyo

Swissmedic has granted approval of Lixiana for the prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation…

Daiichi Sankyo logo

U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk

Industry news, News / 9 January 2015 / Daiichi Sankyo

U.S. FDA approves Daiichi Sankyo’s once-daily SAVAYSA™ (edoxaban) tablets for reduction of stroke risk in non-valvular atrial fibrillation and for the treatment of venous thromboembolism…

Daiichi Sankyo logo

Daiichi Sankyo launches new formulation of LIXIANA® 60 mg Tablets (edoxaban) in Japan

Industry news / 8 December 2014 / Daiichi Sankyo

Daiichi Sankyo Company, Limited announced that it has launched a new formulation of LIXIANA®60 mg Tablets…

Boehringer Ingelheim logo

Pradaxa® gains EU approval for treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism

Industry news / 6 June 2014 / Boehringer Ingelheim

Boehringer Ingelheim announces that Pradaxa® (dabigatran etexilate) has been approved by the European Commission for the treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism…

Boehringer Ingelheim logo

FDA approves Pradaxa® for treatment and reduction in risk of recurrent deep vein thrombosis (DVT) and pulmonary embolism (PE)

Industry news / 8 April 2014 / Boehringer Ingelheim

Boehringer Ingelheim announced that the U.S. Food and Drug Administration has approved Pradaxa® (dabigatran etexilate) for the treatment of DVT and PE…

Daiichi Sankyo logo

Once-daily edoxaban evaluated in two subgroup analyses of East Asian patients from the largest comparative phase 3 trials of a novel oral anticoagulant

Industry news / 24 March 2014 / Daiichi Sankyo

Daiichi Sankyo Company, Limited announced late-breaking data from two pre-specified subgroup analyses of East Asian patients with non-valvular atrial fibrillation or venous thromboembolism enrolled in two phase 3 edoxaban studies…

Daiichi Sankyo logo

Daiichi Sankyo submits SAVAYSA(TM) (edoxaban) tablets New Drug Application to the U.S. FDA

Industry news / 9 January 2014 / Daiichi Sankyo

Submission based on the two largest comparative phase 3 clinical trials of a novel oral anticoagulant in patients with non-valvular atrial fibrillation or symptomatic venous thromboembolism…

Daiichi Sankyo logo

Daiichi Sankyo submits edoxaban Marketing Authorisation Application to the EMA for once-daily use for stroke prevention in atrial fibrillation and for the treatment and prevention of recurrence of venous thromboembolism

Industry news / 8 January 2014 / Daiichi Sankyo

Daiichi Sankyo is seeking approval for edoxaban for the prevention of stroke and systemic embolic events in patients with non-valvular atrial fibrillation…

 

Win an Amazon Gift Card worth up to €100!TAKE OUR SURVEY
+ +